Terug
38
Ook genoteerd als
RYHTY
OTC
Dagbereik
€ 1,41
€ 3,11
52-Weeksbereik
€ 1,21
€ 3,11
Volume
1
50D / 200D Gem.
€ 1,51
/
€ 1,51
Vorige Slotkoers
€ 1,41
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -3,3 | 0,4 |
| P/B | 0,3 | 2,9 |
| ROE % | -10,1 | 3,8 |
| Net Margin % | -61,2 | 3,9 |
| Rev Growth 5Y % | 12,1 | 10,0 |
| D/E | 0,4 | 0,2 |
Belangrijkste Punten
Revenue grew 12,08% annually over 5 years — strong growth
Earnings declined -9248,29% over the past year
Debt/Equity of 0,40 — conservative balance sheet
Generating 302,89M in free cash flow
PEG of 0,00 suggests growth is underpriced
Groei
Revenue Growth (5Y)
12,08%
Revenue (1Y)9,72%
Earnings (1Y)-9248,29%
FCF Growth (3Y)17,72%
Kwaliteit
Return on Equity
-10,07%
ROIC-1,49%
Net Margin-61,20%
Op. Margin-16,57%
Veiligheid
Debt / Equity
0,40
Current Ratio0,24
Interest Coverage-0,85
Waardering
P/E Ratio
-3,28
P/B Ratio0,34
EV/EBITDAN/A
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 9,72% | Revenue Growth (3Y) | 12,89% |
| Earnings Growth (1Y) | -9248,29% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 12,08% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 713,80M | Net Income (TTM) | -436,83M |
| ROE | -10,07% | ROA | -3,62% |
| Gross Margin | 100,00% | Operating Margin | -16,57% |
| Net Margin | -61,20% | Free Cash Flow (TTM) | 302,89M |
| ROIC | -1,49% | FCF Growth (3Y) | 17,72% |
| Safety | |||
| Debt / Equity | 0,40 | Current Ratio | 0,24 |
| Interest Coverage | -0,85 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | -3,28 | P/B Ratio | 0,34 |
| P/S Ratio | 2,01 | PEG Ratio | 0,00 |
| EV/EBITDA | N/A | Dividend Yield | 0,00% |
| Market Cap | 1,43B | Enterprise Value | 3,11B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 713,80M | 650,53M | 560,11M | 503,76M | 452,41M |
| Net Income | -436,83M | 4,78M | 257,84M | 692,87M | 423,06M |
| EPS (Diluted) | -0,61 | 0,01 | 0,50 | 1,31 | 0,80 |
| Gross Profit | 713,80M | -1,35M | -19,77M | 1,82M | 24,74M |
| Operating Income | -118,26M | -69,61M | -19,77M | 1,82M | 24,74M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 12,06B | 13,08B | 12,51B | 10,97B | 9,17B |
| Total Liabilities | 7,80B | 8,67B | 7,85B | 7,53B | 6,34B |
| Shareholders' Equity | 4,26B | 4,42B | 4,66B | 3,43B | 2,83B |
| Total Debt | 1,70B | 2,57B | 2,34B | 2,59B | 2,29B |
| Cash & Equivalents | 17,66M | 41,81M | 27,88M | 28,31M | 20,17M |
| Current Assets | 216,02M | 824,61M | 775,84M | 741,50M | 600,85M |
| Current Liabilities | 889,82M | 373,45M | 255,56M | 304,07M | 138,11M |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#464 of 820
Recente Activiteit
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026